- Neoadjuvant therapy impact in early pancreatic cancer: “bioborderline” vs. “non-bioborderline”
-
Taboada AGM, Lominchar PL, Martínez MF, García-Alfonso P, Martin AM, Asencio JM
- KMID: 2536387
- Ann Hepatobiliary Pancreat Surg.
- 2022 Nov;26(4):363-374.
- doi: 10.14701/ahbps.22-023
Backgrounds/Aims: To analyze the results of the neoadjuvant treatment of patients in our center with early pancreatic cancer. Methods: Eighty-four patients with early pancreatic cancer (I–II) were included, of which 59... -
- CITED
-
- Close
- SHARE
-
- Close
